Patents by Inventor Michael Filbin

Michael Filbin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260078428
    Abstract: The disclosure relates generally to methods and compositions for cryopreservation and processing of blood for single-cell RNA-sequencing. More particularly, the disclosure relates to methods and compositions for preserving and processing whole blood to enable diagnosing and/or treating sepsis via single-cell RNA sequencing (scRNA-seq). In certain aspects, the methods and compositions disclosed herein may be employed in diagnosis and treatment of subjects having or at risk of having sepsis.
    Type: Application
    Filed: September 16, 2025
    Publication date: March 19, 2026
    Applicants: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Roby BHATTACHARYYA, Michael FILBIN, Alyssa DUBOIS, Peter ANKOMAH
  • Patent number: 10528701
    Abstract: Systems and methods are disclosed for sepsis care management. First data regarding a patient and second data regarding a clinician's treatment of a patient are received by at least one processor. The first data regarding the patient is processed to assess a likelihood that the patient would benefit from administration of each of one or more critical actions for treatment of sepsis, wherein at least one of the one or more critical actions relates to a request for at least one additional diagnostic action. A target treatment protocol, comprising a decision for each of the one or more critical actions, is determined based on the assessed likelihoods. The second data regarding a clinician's treatment of the patient is compared to the target treatment protocol and a notification is provided to the clinician if the second data is incompatible with the target treatment protocol.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: January 7, 2020
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Thomas Heldt, Andrew Tomas Reisner, Michael Filbin
  • Patent number: 10327709
    Abstract: A method to quantitatively predict a patient's serum lactate level, comprising measuring arterial blood pressure and heart rate from the patient, computing estimates of one or more cardiovascular parameters from the measured arterial blood pressure and heart rate, providing one or more classifiers that have been trained on a training data set including a reference set of arterial blood pressure, heart rate, and serum lactate levels and using the one or more classifiers to estimate the serum lactate level of the patient.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: June 25, 2019
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Thomas Heldt, Max H. Dunitz, George Cheeran Verghese, Andrew Tomas Reisner, Michael Filbin
  • Publication number: 20170042483
    Abstract: A method to quantitatively predict a patient's serum lactate level, comprising measuring arterial blood pressure and heart rate from the patient, computing estimates of one or more cardiovascular parameters from the measured arterial blood pressure and heart rate, providing one or more classifiers that have been trained on a training data set including a reference set of arterial blood pressure, heart rate, and serum lactate levels and using the one or more classifiers to estimate the serum lactate level of the patient.
    Type: Application
    Filed: August 12, 2016
    Publication date: February 16, 2017
    Inventors: Thomas Heldt, Max H. Dunitz, George Cheeran Verghese, Andrew Tomas Reisner, Michael Filbin
  • Publication number: 20160239611
    Abstract: Systems and methods are disclosed for sepsis care management. First data regarding a patient and second data regarding a clinician's treatment of a patient are received by at least one processor. The first data regarding the patient is processed to assess a likelihood that the patient would benefit from administration of each of one or more critical actions for treatment of sepsis, wherein at least one of the one or more critical actions relates to a request for at least one additional diagnostic action. A target treatment protocol, comprising a decision for each of the one or more critical actions, is determined based on the assessed likelihoods. The second data regarding a clinician's treatment of the patient is compared to the target treatment protocol and a notification is provided to the clinician if the second data is incompatible with the target treatment protocol.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 18, 2016
    Inventors: Thomas Heldt, Andrew Tomas Reisner, Michael Filbin